Plasma DNA as a “liquid biopsy” incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer-Reference-Cited by-同舟云学术

Plasma DNA as a “liquid biopsy” incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer

Published:2020-06-19 Issue:3 Volume:182 Page:665-677
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Chamberlin Mary D.,Wells Jason D.,Shee Kevin,Bean Jennifer R.,Marotti Jonathan D.,Wells Wendy A.,Trask Heidi W.,Kolling Fred W.,Bhatt Ananta,Kaufman Peter A.,Schwartz Gary N.,Gemery John M.,McNulty Nancy J.,Tsapakos Michael J.,Barth Richard J.,Arrick Bradley A.,Gui Jiang,Miller Todd W.^ORCID

Funder

National Cancer Institute

Norris Cotton Cancer Center

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-020-05714-2.pdf

Reference50 articles.

1. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC (2005) ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102(10):3788–3793. https://doi.org/10.1073/pnas.0409773102

2. Martin LA, Pancholi S, Farmer I, Guest S, Ribas R, Weigel MT, Thornhill AM, Ghazoui Z, A'Hern R, Evans DB, Lane HA, Johnston SR, Dowsett M (2012) Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo. Breast Cancer Res: BCR 14(5):R132. https://doi.org/10.1186/bcr3330

3. Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, Ebbesen SH, Ainscough BJ, Ramu A, Iyer G, Shah RH, Huynh T, Mino-Kenudson M, Sgroi D, Isakoff S, Thabet A, Elamine L, Solit DB, Lowe SW, Quadt C, Peters M, Derti A, Schegel R, Huang A, Mardis ER, Berger MF, Baselga J, Scaltriti M (2015) Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature 518(7538):240–244. https://doi.org/10.1038/nature13948

4. Hu ZY, Xie N, Tian C, Yang X, Liu L, Li J, Xiao H, Wu H, Lu J, Gao J, Hu X, Cao M, Shui Z, Xiao M, Tang Y, He Q, Chang L, Xia X, Yi X, Liao Q, Ouyang Q (2018) Identifying circulating tumor DNA mutation profiles in metastatic breast cancer patients with multiline resistance. EBioMedicine 32:111–118. https://doi.org/10.1016/j.ebiom.2018.05.015

5. Weinberg AL, Carter D, Ahonen M, Alarid ET, Murdoch FE, Fritsch MK (2007) The DNA binding domain of estrogen receptor alpha is required for high-affinity nuclear interaction induced by estradiol. Biochemistry-Us 46(31):8933–8942. https://doi.org/10.1021/bi700018w

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis, biology and epidemiology of oligometastatic breast cancer;The Breast;2021-10